Anavex Life Sciences Corp (AVXL)

[nidan7500]

Penny double:

Seams like desperation moves to me and copy cats of the new process that Anavex is putting down, evidently with some type of success or they wouldn't be trying to duplicate our clinical process. IMO

We might ask...SO WHAT? but, that's a lot of money. Not clear how far along this company is in the AD/other CNS disease diagnostic process. As we hhere know, it's one thing to state what is theoretically possible, it is another thing to PROVE IT and have the FDA agree, you have proof from a validated licensed process. Considering AVXL recent patent news ref use of "Cognision" w/dose trials this might be seen as a different path to FDA PM conformance/compliance. In any case, looks like they finally got the FDA memo on the Amyloid thesis. kinda tough news for those BIIB contractor folks already doing trials w/Amyloid thesis variant, that must have been an interesting NP planning meeting. Oh Well, that's just how BIIB does business. SURPRISE.
Lots of smart people here, lets spread out and see what we can find out about both Skyhawk Therapeutics and C4 Therapeutics. Will RNA studies get them AD patient-treatment/recovery or is this another Evergreen Program from BIIB (remember, that's how they do business)? Are either partnership establishments FDA licensed? Since we know that any establishment doing medical device diagnostics must have filed w/FDA -IND-510k, Like Cognision did (search FDA site for K141316). Also note AVXL work described in the patent was started in 2015-2017 with work on AD patients in a real trial. Does that mean about a 2 year head start?

So, it's possible BIIB is onto something with this RNA tool set. They must have done a lot of DD before they signed up (well we'll see, or was it just a reflex). If they did any DD and if this is actually real then we will hear a lot from them about new ground breaking/breakthrough stuff, B/C that is what they do. Count on lots of BIIB PR's. Spread out and get some relevant factual information, a key point would be any evidence of work done w/FDA or other regulatory bodies using RNA tool. We should expect to hear from them soon. BTW, our A2-73 patent news probably shook the bushes elsewhere, so Pilots and crews report to your ready rooms. We should expect similar news from other clinical trial firms w/in next months. That's is actually good news as it tends to validate the next school of thinking. We should also expect to hear something from the FDA once multiple BP announce their NEW STUFF. FDA will at some point do a conference on the NEW TRAILS process, IMO.